Letrozole withdrawal response in locally advanced breast cancer by Lambertini, M et al.
Annals of Oncology 22: 1927–1932, 2011letters to the editor
Letrozole withdrawal response in
locally advanced breast cancer
Antiestrogen therapies are among the most effective breast
cancer treatments. Third generation aromatase inhibitors are
superior to tamoxifen in both early and advanced breast cancer
patients. Despite the endocrine sensitivity of the majority of
breast tumors, a significant proportion of patients experiences
disease progression due to either an inherently intrinsic or
acquired resistance to endocrine agents. Therefore, a common
clinical practice is the sequential use of different hormonal
treatments.
We describe the case of a 77-year-old female presented
with a locally advanced breast cancer of the upper outer
quadrant of the left breast, which measured 3 · 3.5 cm; an
enlarged, fixed axillary node of 3 cm in diameter was palpated
(T2 N2a, clinical stage: IIIA). Tumor biopsy showed an
infiltrating ductal carcinoma, with a positive staininig for
estrogen receptor (ER) and progesterone receptor (PgR)
(ER: 99%, PgR: 93%), a high proliferative index (Ki67: 38%),
and without overexpression of Her2-neu. The positron
emission tomography/computed tomography (PET/CT)
evaluation showed high metabolic activity in both the breast
[maximum standardized uptake value (SUVmax): 5.6] and the
axillary node (SUVmax: 6.5). The main comorbidity of the
patient was a hepatitis C virus (HCV)-related cirrhosis: she had
elevated liver function tests [aspartate aminotransferase : 160
U/l; alanine transaminase : 123 U/l; c-glutamyltransferase
(c-GT): 111 U/l; alkaline phosphatase : 279 U/l; total
bilirubin: 1.48 mg/dl], bleeding disorder [quick value: 45%;
international normalized ratio : 1.63], thrombocytopenia
(platelet count: 40 000), and the presence of HCV in the
blood (quantitative HCV-RNA: 677 000 UI/ml). Because of
her clinical condition and the local extension of the tumor,
the surgical resection was not possible. Treatment with
letrozole 2.5 mg/die was initiated with close monitoring of
liver function. After 8 months of therapy, a complete
response was documented both by clinical examination and by
PET/CT, which showed the disappearance of the previous sites
with high metabolic activity. After 4 months, clinical disease
progression was observed with a volume increase of both the
breast and the axillary node. Letrozole was discontinued and,
due to the worsening of her liver function, no second-line
anticancer therapy was initiated. After 2 months, despite the
absence of anticancer treatment, a complete clinical response
was observed with the disappearance of the breast and axillary
node lesions: she continues to have a complete sustained
withdrawal response on 10 months later.
A withdrawal response to antihormonal therapy is
a potential therapeutic maneuver for patients with
progressive prostate cancer (antiandrogen withdrawal) [1],
while only few cases have been reported in the literature for
breast cancer. Tumor response after withdrawal of tamoxifen
was first described by Legault-Poisson et al. [2] and then in
other two cases [3, 4]; two cases of aromatase inhibitor
withdrawal response in metastatic breast cancer have been
reported [5, 6]. Bhide and Rea [5] reported a case of
complete response after exemestane withdrawal in a patient
with a metastasis in the supraclavicular fossa, and Cigler
and Goss [6] described a partial response in bone and
liver metastasis after withdrawal of goserelin and letrozole
combination. In both the above reported cases, a response
to aromatase inhibitor withdrawal was observed in patients
with metastatic breast cancer previously treated with three
or more lines of antihormonal therapies.
Here, we report the withdrawal response to letrozole alone
in a patient with locally advanced breast cancer who didn’t
receive any previous anticancer therapy.
There are some preclinical data, both in vitro and in mouse
xenograft models [7, 8], that support a rationale to use
antihormonal therapy withdrawal in the treatment of breast
cancer. As postulated by Song et al. [9], long-term estrogen
deprivation sensitizes breast cancer cells to proapoptotic
effects of reintroduction of low doses of estradiol, which are
normally only seen at higher doses; the extremely low-estrogen
environment encountered in the presence of antihormonal
therapy may sensitize the tumor cells to low estrogen levels
found in postmenopausal women after antihormonal therapy
withdrawal: these low levels of estrogen may be sufficient to
induce a tumor response.
Antihormonal therapy withdrawal could be considered
a therapeutic measure, at least in some selected patients, such
as patients treated with two or more hormone therapies with
a good clinical response before disease progression and
without life-threatening metastases. A short duration of
aromatase inhibitor or tamoxifen withdrawal may be
considered before starting additional anticancer treatment.
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